The European Journal of Pharmaceutical Sciences is a prestigious academic journal dedicated to advancing the field of pharmaceutical science. Published by Elsevier, the journal boasts an impressive impact factor and is categorized in the Q1 quartile for pharmaceutical science as of 2023, signifying its influence and reputation within the academic community. With a Scopus ranking of #20 out of 183 in the fields of pharmacology, toxicology, and pharmaceutics, the journal provides a vital platform for researchers and practitioners to disseminate innovative studies and groundbreaking research that push the boundaries of drug development and delivery. Based in the Netherlands and operating since 1993, the journal seeks to cover a broad scope of topics related to pharmaceutical sciences, encouraging rigorous evaluations and discussions that enhance the understanding and application of this critical field. The absence of open access underscores the commitment to maintaining high scholarly standards, while still offering avenues for libraries and institutions to provide access to cutting-edge research. As the journal converges towards its 2024 milestones, it continuously aims to foster a vibrant exchange of knowledge among its diverse readership, comprising committed researchers, professionals, and students.

Drug Metabolism Reviews is a premier journal dedicated to the dissemination of scientific research and reviews in the field of pharmacology, toxicology, and pharmaceutics, published by Taylor & Francis Ltd. With its inception dating back to 1972, this journal has consistently provided an authoritative platform for scholars and professionals from diverse disciplines to explore the intricate mechanisms of drug metabolism and their implications for therapeutic applications. The journal enjoys commendable rankings, placing in the Q2 quartile for Pharmacology (medical) and the Q1 quartile in the miscellaneous subfield, signaling its significant impact within the community. Notably, it is recognized within the top 96th percentile in General Pharmacology, Toxicology and Pharmaceutics, affirming its esteemed position among academic publications. Although it operates under a subscription model, Drug Metabolism Reviews remains an essential resource for researchers, professionals, and students seeking to deepen their understanding of drug interactions, safety, and efficacy. The insights shared within its pages contribute vital knowledge to the global discourse on drug development and personalized medicine.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.

ADMET and DMPK is a premier open-access journal published by IAPC PUBLISHING since 2013, focusing on the rapidly evolving fields of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) and DMPK (Drug Metabolism and Pharmacokinetics). Catering to researchers, professionals, and students in the realms of pharmacology, toxicology, and medicinal chemistry, this journal plays a crucial role in fostering innovation and collaboration within the interdisciplinary landscape of drug development. With an impressive Q1 ranking in Pharmacology, Toxicology and Pharmaceutics and ranking in the top percentiles across various categories such as Chemistry and Health, ADMET and DMPK provides a reputable platform for high-quality publications. Its global reach, complemented by its open-access model, ensures that valuable research is accessible to a wide audience. As we converge towards 2024, this journal remains dedicated to advancing knowledge and practices that shape the future of drug discovery and safety, making it an essential resource in the scientific community.

AAPS Journal, published by Springer in the United States, is a leading peer-reviewed journal dedicated to the advancement of research in the field of Pharmaceutical Sciences. With an impressive Q1 rank in its category and a position within the 81st percentile of Scopus rankings, it serves as a vital resource for researchers and professionals seeking to disseminate impactful findings and innovative methodologies. The journal publishes high-quality original research, review articles, and technical reports aimed at addressing the multifaceted challenges in pharmacology, toxicology, and pharmaceutics. Operating under an Open Access model, AAPS Journal ensures broad dissemination of knowledge, contributing to the enhanced visibility and accessibility of research outputs. With a publication window spanning from 1999 to 2024, it continues to shape the future of pharmaceutical research and its applications. Researchers, students, and industry professionals will find a valuable repository of cutting-edge knowledge in this esteemed journal.

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

Advances in Pharmacological and Pharmaceutical Sciences is a premier open-access journal published by Hindawi Ltd. based in the United Kingdom. Established in 2020, the journal swiftly garnered attention for its commitment to disseminating high-quality research in the realms of pharmacology, toxicology, and pharmaceutical sciences. It holds a commendable impact with notable quartile rankings, including Q2 in both Organic Chemistry and Pharmacology, indicating its importance within these disciplines. By embracing an open-access model, the journal ensures that research findings are widely available, promoting increased visibility and collaboration among researchers, professionals, and students globally. With an ongoing convergence of insights projected through 2024, Advances in Pharmacological and Pharmaceutical Sciences aims to address critical issues and advancements in drug development and therapeutic practices, making it an invaluable resource for those at the forefront of scientific inquiry in pharmacology and related fields.

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

Pharmaceutical Medicine is a leading journal published by SPRINGER INT PUBL AG, dedicated to the field of pharmacology and pharmaceutical sciences. With ISSN 1178-2595 and E-ISSN 1179-1993, this journal serves as an essential platform for researchers and professionals to share groundbreaking findings and advancements in medication efficacy, safety, and innovative therapeutic strategies. Recognized for its contribution to the field, Pharmaceutical Medicine holds an impressive Q2 ranking in both Pharmacology and Medical Pharmacology categories, further underscored by its competitive Scopus rankings—positioned at 100/272 (63rd percentile) in Medical Pharmacology and 156/313 (50th percentile) in Pharmacology, Toxicology, and Pharmaceutics. Although it primarily operates on a traditional subscription basis, its robust academic reputation continues to attract a diverse readership worldwide. Addressed in the United Kingdom with facilities in Switzerland, the journal publishes authoritative articles from its inception in 2000 through to 2024, making it a pivotal resource for those seeking to enhance their understanding and application of pharmacological principles in clinical practice and research.